Information about Benefix (Nonacog alfa):
Benefix (Nonacog alfa) is a medication used to treat and prevent bleeding episodes in patients with hemophilia B, a genetic disorder where the blood doesn’t clot properly due to a deficiency of clotting factor IX.
Recombinant form of human factor IX, which is crucial for proper blood clotting. It is produced using recombinant DNA technology, which avoids the use of human or animal blood products.
Product Highlights:
- Nonacog alfa (recombinant human coagulation factor IX) is active ingredient of Benefix.
- Specifically designed for the treatment and prevention of bleeding episodes in patients with hemophilia B (factor IX deficiency).
Key Ingredient:
Key Benefits:
- Helps prevent bleeding episodes and reduces the frequency of bleeding in hemophilia B patients.
- Provides immediate control over bleeding during episodes or surgical procedures.
- Being a recombinant factor, it may reduce the risk of developing inhibitors compared to some older treatments.
Directions for Use:
- Administered intravenously. The dosage and frequency depend on the patient’s specific needs and the severity of their hemophilia.
- Reconstitute the powder with the provided diluent before injection.
- Regular monitoring of blood levels and patient response is essential to adjust dosing as needed.
Safety Concern:
- Potential for allergic reactions, including anaphylaxis. Monitoring for any signs of an allergic response during and after administration is necessary.
- There is a risk of developing inhibitors (antibodies) against the factor IX, which can reduce the effectiveness of the treatment.
Avoid Benefix (Nonacog alfa) If:
- You have a known hypersensitivity or allergy to Nonacog alfa or any of its components.
- You have existing inhibitors against factor IX, which may render this treatment ineffective.
